Last updated: May 24, 2026
Pasireotide pamoate suppliers: manufacturers, contract sources, and key supply risks
Pasireotide pamoate supply is dominated by the originator’s supply chain for SIGNIFOR (pasireotide) LAR (injectable long-acting). The active ingredient is typically handled through controlled external manufacturing, with dosing-formulation and sterile fill-finish performed by specialized CDMOs under quality agreements. Practical supplier identification for contract manufacturing is constrained by limited public disclosure of complete sub-supplier lists in the open record.
Who manufactures pasireotide pamoate API for SIGNIFOR and SIGNIFOR LAR?
A complete, publicly enumerated roster of all pasireotide pamoate API suppliers is not available from public documents at the level needed for a definitive “all suppliers” list.
Where does pasireotide pamoate API typically come from in the peptide space?
Pasireotide is a synthetic cyclic peptide. In commercial practice, API supply for controlled peptide injectables usually involves:
- Small set of qualified peptide API manufacturers producing pasireotide peptide substance and pairing with pamoate salt formation.
- Salt formation and isolation steps often performed by the API supplier or a tightly controlled partner with peptide-quality systems.
- Regulatory-facing change control that makes qualification of new API sources slow and expensive.
What can be confirmed from public filings about supply chain structures?
Public disclosure around pasireotide pamoate supply more often identifies:
- Marketing authorization holder / label drug product manufacturer
- Sterile manufacturing and packaging sites
- Quality/CGMP oversight responsibilities
than it enumerates API sub-suppliers.
Which companies supply SIGNIFOR LAR (pasireotide pamoate) in finished drug product form?
Finished-dose supply for SIGNIFOR LAR is executed through controlled sterile manufacturing networks. Public records typically show one or a limited number of drug product manufacturing sites responsible for:
- Lyophilized or sterile powder production (depending on site-specific manufacturing design)
- Aseptic operations
- Kit packaging for administration
A definitive “supplier list” covering every company manufacturing every lot in every geography is not fully extractable from publicly available data without complete access to procurement-level vendor qualification lists.
What are the key CDMO roles in pasireotide pamoate injection manufacturing?
Pasireotide pamoate injectable long-acting supply involves multiple specialized process steps that map to CDMO capability buckets.
1) Peptide API synthesis and pamoate salt formation
Supplier responsibility typically includes:
- Peptide synthesis and purification
- Characterization and release testing
- Salt formation to pasireotide pamoate
- Stability program alignment with drug product needs
2) Long-acting delivery system manufacturing
For LAR (long-acting release), suppliers must support:
- Particle or depot-formulation engineering
- Sterile and controlled handling for final dosage forms
- Consistent drug release profile and batch-to-batch reproducibility
3) Sterile fill-finish and packaging
Aseptic processing and packaging suppliers handle:
- Sterile filtration/aseptic filling logic (depending on manufacturing scheme)
- Vial/syringe component supply and container closure system controls
- Kit assembly and labeling controls for distribution
How do you identify pasireotide pamoate suppliers from regulatory records (Orange Book, EU EPAR, label MAHs)?
Best practice for supplier mapping uses the regulated “chain of custody” visible in:
- FDA labeling/PLR documents (US)
- EU EPAR / national approval documents (EU)
- US prescribing information “Manufactured for” or “Distributed by” statements
- Drug master file references when accessible indirectly through regulatory exhibits
Orange Book approach (US)
For combination products where peptide APIs are controlled and manufacturing sites are limited, Orange Book listings often help identify:
- The applicant/holder
- Whether exclusivity attaches to particular strengths/packaging
But it often does not list every upstream API or CDMO sub-supplier.
EU approach
EPAR documentation more commonly identifies manufacturing sites and responsible parties by location, which is the most practical way to enumerate “finished drug product manufacturing suppliers” from open sources.
What manufacturing/IP constraints limit switching pasireotide pamoate suppliers?
Supplier switching for peptide long-acting injectables is constrained by both technical and IP factors.
Technical constraints
- Depot formulation and release profile are sensitive to upstream material attributes (impurity profile, particle behavior, salt form quality).
- Peptide manufacturing changes can shift degradation and impurity patterns that require bridging studies.
IP and regulatory constraints
- Process patents and formulation patents can constrain “design around” manufacturing choices.
- CGMP change control and comparability packages create lead-time barriers for new suppliers.
What supply risks exist for pasireotide pamoate (API shortage, sterile manufacturing bottlenecks, raw material)?
For long-acting peptide injectables, the main supply risk categories are:
- API peptide shortages tied to limited qualified peptide synthesis capacity
- Salt formation and specialized purification bottlenecks
- Sterile fill-finish capacity constraints for depot injectables
- Single-site dependency risk when the marketed product relies on one primary depot manufacturing site
Open records rarely provide forward-looking supplier-level risk scoring, but the structure of peptide drug supply typically leads to concentrated capacity.
How do biosimilar or generic development efforts affect pasireotide pamoate supplier landscape?
Pasireotide pamoate is a small peptide; biosimilar pathways do not apply in the standard sense. The supplier landscape impact comes mainly from:
- Generic long-acting formulations in the US and EU
- Follow-on depot technologies and line extensions
- API availability for generic manufacturers that seek multiple supply sources
In practice, generic entrants usually qualify a narrow set of API and sterile suppliers early, then expand if commercial demand supports it.
What is the competitive landscape for pasireotide pamoate manufacturing and contract supply?
Competitive landscape in this niche is shaped by:
- Limited number of CDMOs with long-acting sterile depot expertise
- Restricted peptide API manufacturing capacity for cyclic peptides
- Heavy QA and analytical requirements for peptide purity and depot release characterization
A complete list of all qualified competitors and CDMOs cannot be reliably produced from public sources alone at the granularity required for contracting decisions.
Key Takeaways
- Public sources generally identify the finished drug product manufacturing sites and responsible marketing entities more reliably than upstream pasireotide pamoate API sub-suppliers.
- Supplier switching for pasireotide pamoate is constrained by depot formulation sensitivity and peptide impurity attribute control, increasing qualification time.
- Supply risk concentrates around peptide synthesis capacity, salt formation/purification, and long-acting sterile depot manufacturing capability.
- For contracting or sourcing decisions, the most actionable public route is to map label/MAH manufacturing locations first, then layer in upstream supplier qualification through DMPP/DMF and quality documentation in vendor onboarding.
FAQs
1) How can I list pasireotide pamoate manufacturing sites for a sourcing shortlist from public documents?
Use the product’s label/EPAR manufacturing location sections to build the finished drug product site shortlist, then validate upstream API paths during vendor qualification.
2) Are there multiple pasireotide pamoate API sources for SIGNIFOR LAR?
Multiple sources may exist for API supply in practice, but open public records often do not enumerate them comprehensively.
3) What CDMO capabilities are required to manufacture pasireotide pamoate long-acting injections?
Peptide API handling plus depot/long-acting formulation experience and sterile manufacturing and kit packaging capabilities.
4) What causes batch failures or rejections when switching pasireotide suppliers?
Differences in peptide impurity profile, salt form consistency, and depot release characteristics under comparability criteria.
5) Do generic or follow-on long-acting pasireotide products change supplier availability?
They can expand qualified supplier demand over time, but the initial qualified supply base typically stays small due to qualification burden.
References
- FDA. Prescribing information and regulatory documents for SIGNIFOR (pasireotide) and SIGNIFOR LAR (pasireotide pamoate). U.S. Food and Drug Administration.
- EMA. EPAR documents for SIGNIFOR/SIGNIFOR LAR (pasireotide). European Medicines Agency.
